INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...
today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis.